Foresite Capital leads Series B round for Allergen Research Corp

By Iris Dorbian — 11 months ago

San Mateo, California-based Allergen Research Corp, which develops treatments for food allergies, has closed $80 million in Series B funding. Foresite Capital led the round with participation from Longitude Capital, Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. In conjunction with the funding, Dr. Jim Tananbaum, CEO and managing director of Foresite Capital and Stacey Seltzer, a partner at Aisling Capital, have been added to ARC’s board of directors.


Alimera Sciences Inks $40m Series A led by Palo Alto Investors

By Angela Sormani — 4 years ago

Alimera Sciences, a biopharmaceutical company specialising in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has secured a $40 million Series A financing. Palo Alto Investors acted as the lead investor in the offering, with Sofinnova Ventures and New Enterprise Associates also participating. PRESS RELEASE Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that […]


Yaupon Therapeutics Adds $14.4M Series D

5 years ago

Malvern, Penn.-based Yaupon Therapeutics Inc. has closed on $14.4 million in Series D financing. The company, a specialty pharmaceutical maker, is backed by Vivo Ventures, Palo Alto Investors, Burrill & Company and Aperture Venture Partners. The new funds will help the company go through the regulatory review process for a drug designed to treat early stage mycosis fungoides, the most common type of cutaneous T-cell lymphoma.


Revance Therapeutics Closes on $45M

5 years ago

Revance Therapeutics Inc., a drug developer focused on dermatology and aesthetic medicine, has raised $45 million in new capital from Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation. Jonathan Tunnicliffe, a partner at NovaQuest, will join the Revance board as a result of the round. Revance closed a $25.62 million in Series D funding in late 2009.


Sex Toy Maker JimmyJane Raises $2M

By Alexander Haislip — 6 years ago

Sex toy maker JimmyJane raised $2 million from a group of investors in its Series E round, according to a new regulatory filing. This brings the company’s total to $8.3 million.

JimmyJane, a startup looking to become the Montblanc of vibrating sex toys, has raised money from investors such as technology hedge fund Palo Alto Investors and a limited liability company controlled by venture capitalist Tim Draper, documents show.

Since its initial institutional financing round, the company has launched several new products. Its original line of high-end toys were pricey, starting at $175 and ranging up to $3,250 for its diamond-studded platinum vibrator. It has since added several down-market offerings, such as a the $90 “Iconic Rabbit” and a $36 vibrating ring.


Fisker Continues Fundraising: $65M

By Alexander Haislip — 7 years ago

The electric car wars continue as Fisker Automotive gets a $65 million cash injection from Kleiner Perkins, hedge fund Palo Alto Investors and the Qatar Investment Authority (QIA). Earth2Tech has the story and a reminder about the company’s ongoing legal battle.

The interesting thing here, outside the sexy looking car, is the source of the financing: an early stage venture firm (now growth investor when it comes to “greentech”), a hedge fund and the state-backed investment fund of an petrochemical-rich middle-eastern nation. Which of these investors doesn’t belong?